No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ACET Adicet Bio
- 1.680
- -0.130-7.18%
Close Apr 26 16:00 ET
- 1.721
- +0.041+2.46%
Post 19:30 ET
138.04MMarket Cap-507P/E (TTM)
1.825High1.660Low1.25MVolume1.810Open1.810Pre Close2.17MTurnover2.55%Turnover RatioLossP/E (Static)82.17MShares7.50052wk High0.81P/B82.50MFloat Cap1.10052wk Low--Dividend TTM49.10MShs Float214.348Historical High--Div YieldTTM9.12%Amplitude0.931Historical Low1.734Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target
Express News | Adicet Today Presented Abstract Featuring Preclinical Data Highlighting ADI-270 At ASGCT27th Annual Meeting
Express News | Adicet Bio Inc - Preclinical Findings Showed Robust Anti-Tumor Activity of Adi-270 in Multiple Cd70-Positive Solid and Hematological Cancer Models
Express News | Adicet Bio Inc - on Track to File an Investigational New Drug (Ind) Application for Adi-270 in 2Q 2024
Express News | Adicet Bio Inc - Adi-270 Demonstrated Enhanced Functional Potency and Resilience in Tumor Microenvironment
Express News | Adicet Bio Highlights Preclinical Data Supporting Ind Readiness for Adi-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (Asgct) 27TH Annual Meeting
Comments
Nice!
$Adicet Bio(ACET.US$ Adicet Bio Highlights Preclinical Data Supporting Ind Readiness for Adi-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (Asgct) 27TH Annual Meeting. Preclinical Findings Showed Robust Anti-Tumor Activity of Adi-270 in Multiple Cd70-Positive Solid and Hematological Cancer Models
Watching for this!
$Adicet Bio(ACET.US$ Adicet Bio On Track to File IND for ADI-270 in Renal Cell Carcinoma in 2Q >ACET
Dow Jones· 5 mins ago
Dow Jones· 5 mins ago
Update
$Adicet Bio(ACET.US$ Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
7 MINUTES AGO, 4:01 PM EST
VIA BUSINESSWIRE
7 MINUTES AGO, 4:01 PM EST
VIA BUSINESSWIRE
JMP Securities Sticks to Their Hold Rating for Adicet Bio (ACET)
$Adicet Bio(ACET.US$
Analysts monitoring Adicet Bio come to a price target consensus of $14.75
Analysts monitoring Adicet Bio come to a price target consensus of $14.75
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg